The only clinical study that was performed to determine the resveratrol hepatoprotective effect demonstrated that a 500 mg resveratrol dose administrated for 12 weeks caused a significant reduction in inflammatory cytokines, serum cytokeratin-18, NF-kB activation, liver alanine aminotransferase (ALT), and hepatic steatosis when compared to the placebo group in patients with nonalcoholic fatty liver disease (NAFLD) [46]
van Zuuren, E
however, the molecular explanations of this insensitivity remain unknown
Abnormal concentrations of IGF-1 are linked with obesity [6], metabolic syndrome [7], type 2 diabetes [8], atherosclerosis [9], heart failure (HF) [10, 11], and diabetic kidney disease (DKD) [12]
Higher molecular weight forms of GH exist in the circulation, representing GH bound to growth hormone binding proteins (GHBP) (302)